Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

A Single Center Retrospective Study on the Efficacy of Haploidentical Hematopoietic Stem Cell Transplantation in Patients with Myeloid Neoplasms over 50 Years Old

Meng Liu, Xiaoli Wang, Yi Luo, Yanmin Zhao, Jian Yu, Xiaoyu Lai, Lizhen Liu, Huarui Fu, Weiyan Zheng, Jie Sun, Jingsong He, Yi Zhao, Guoqing Wei, Zhen Cai, He Huang, Jimin Shi

Blood (2023) 142 (Supplement 1): 7051.

https://doi.org/10.1182/blood-2023-184513

Published: 2023

Journal Articles

TL-895, a Highly Selective, Covalent Inhibitor of Bruton's Tyrosine Kinase (BTK), Sensitizes Myeloproliferative Neoplasm (MPN)-Blast Phase Stem Cells to Navtemadlin By Targeting Intrinsic Dysregulated MDM2/p53 and NF-Κb Pathways and Disrupting the Protective Tumor Microenvironment (TME)

Xiaoli Wang, Andrew Davis, Xiaoping Su, Muharrem Muftuoglu, Cecile Krejsa, John Mascarenhas, Michael Andreeff, Ronald Hoffman

Blood (2023) 142 (Supplement 1): 4523.

https://doi.org/10.1182/blood-2023-187426

Published: 2023

Journal Articles

Oral Decitabine/Cedazuridine Is a Tolerable and Effective Ambulatory Regimen for Patients with Advanced Myeloproliferative Neoplasms

Ganesh Sivakumar, Shivani Handa, Andrew Srisuwananukorn, Douglas Tremblay, John Mascarenhas, Marina Kremyanskaya, Yelena Ginzburg, Xiaoli Wang, Ronald Hoffman

Blood (2023) 142 (Supplement 1): 1828.

https://doi.org/10.1182/blood-2023-178822

Published: 2023

Journal Articles

Transcriptional and Epigenetic Dysregulation Drives Erythroid and Megakaryocyte Differentiation Bias in the Spleens of Patients with Advanced Myelofibrosis

Rebecca Austin, Madeline Kowalski, Xiaoli Wang, Bettina Nadorp, Audrey Lasry, Zhengxi Sun, Julia Rojo-Tomillo, Andrew Davis, Dimitrios Papaioannou, Rahul Satija, Ioannis Aifantis, Ronald Hoffman

Blood (2022) 140 (Supplement 1): 9584–9585.

https://doi.org/10.1182/blood-2022-170220

Published: 2022

Journal Articles

Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies

Blood (2022) 140 (Supplement 1): 10357–10359.

https://doi.org/10.1182/blood-2022-162539

Published: 2022

Journal Articles

Antigen-guided depletion of anti-HLA antibody–producing cells by HLA-Fc fusion proteins

Ashlee M. Webber, Tara R. Bradstreet, Xiaoli Wang, Hongjie Guo, Christopher A. Nelson, Daved H. Fremont, Brian T. Edelson, Chang Liu

Blood (2022) 140 (16): 1803–1815.

https://doi.org/10.1182/blood.2022016376

Published: 2022

Includes: Supplemental data

Journal Articles

Pharmacodynamic Analysis of CAR-T Cell Persistence in Patients with Hematologic Malignancies Treated with NKTR-255, an IL-15 Receptor Agonist That Enhances CD8 + T-Cells: Preliminary Results from a Phase 1 Study

Cameron J. Turtle, Elizabeth Budde, Krina K. Patel, Miguel-Angel Perales, Andrew J. Cowan, Hayder Saeed, Julio C. Chavez, Alexandre V. Hirayama, Delaney R. Kirchmeier, Murali Janakiram, Kai Wu, Lawrence Fong, Zachary Lee, Neha Dixit, Xiaoli Wang, Kazuharu Kai, Mario Q. Marcondes, Jonathan Zalevsky, Nina Shah

Blood (2021) 138 (Supplement 1): 2815.

https://doi.org/10.1182/blood-2021-147350

Published: 2021

Journal Articles

Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies

Blood (2021) 138 (Supplement 1): 3134.

https://doi.org/10.1182/blood-2021-147758

Published: 2021

Journal Articles

Navtemadlin (KRT-232), a Small Molecule MDM2 Inhibitor, Is More Effective Than Decitabine Against Myeloproliferative Neoplasm-Blast Phase in a Patient-Derived Xenograft Model

Xiaoli Wang, Cing Siang Hu, Virginia Gillespie, Cecile Marie Krejsa, Ronald Hoffman

Blood (2021) 138 (Supplement 1): 3591.

https://doi.org/10.1182/blood-2021-153071

Published: 2021

Journal Articles

The Genetic Architecture of Myeloproliferative Neoplasms-Blast Phase (MPN-BP) Stem Cells

Xiaoli Wang, MD PhD, Raajit K. Rampal, MD PhD, Cing Siang Hu, Noushin Farnoud, PhD, Christopher Famulare, MS, Minal A Patel, MPH, Erin McGovern, BA, Ronald Hoffman, MD

Blood (2019) 134 (Supplement_1): 1677.

https://doi.org/10.1182/blood-2019-128836

Published: 2019

Journal Articles

Combination Treatment with Imetelstat, a Telomerase Inhibitor, and Ruxolitinib Depletes Myelofibrosis Hematopoietic Stem Cells and Progenitor Cells

Cing Siang Hu, Fei Huang, Ronald Hoffman, MD, Xiaoli Wang, MD PhD

Blood (2019) 134 (Supplement_1): 2963.

https://doi.org/10.1182/blood-2019-126189

Published: 2019

Journal Articles

Myeloproliferative Neoplasm (MPN) Blastic Transformation Occurs at the Level of Hematopoietic Stem Cells

Xiaoli Wang, PhD, Cing Siang Hu, Joseph Tripodi, Vesna Najfeld, PhD, Bruce Petersen, MD, Raajit K. Rampal, MD PhD, Noushin Farnoud, Christopher Famulare, MS, John Mascarenhas, MD, Ronald Hoffman, MD

Blood (2018) 132 (Supplement 1): 101.

https://doi.org/10.1182/blood-2018-99-117348

Published: 2018

Journal Articles

Myeloproliferative Neoplasm (MPN) Blastic Transformation Occurs at the Level of Both Short and Long Term Hematopoietic Stem Cells

Xiaoli Wang, PhD, Cing Siang Hu, Raajit K. Rampal, MD PhD, Joseph Tripodi, Vesna Najfeld, PhD, Bruce Petersen, MD, John Mascarenhas, MD, Ronald Hoffman, MD

Blood (2017) 130 (Supplement 1): 2943.

https://doi.org/10.1182/blood.V130.Suppl_1.2943.2943

Published: 2017

Journal Articles

Imetelstat, a Telomerase Inhibitor, Is Capable of Depleting Myelofibrosis Hematopoietic Stem Cells and Progenitor Cells

Cing Siang Hu, Jiajing Qiu, Fei Huang, PhD, Ronald Hoffman, MD, Xiaoli Wang, PhD

Blood (2017) 130 (Supplement 1): 1654.

https://doi.org/10.1182/blood.V130.Suppl_1.1654.1654

Published: 2017

Journal Articles

The Thrombopoietin Receptor (MPL) Is a Selective Marker for the Identification of Hematopoietic Stem Cells from Myelofibrosis Patients

Xiaoli Wang, Cing Siang Hu, Jiajing Qiu, Ronald Hoffman, MD

Blood (2016) 128 (22): 950.

https://doi.org/10.1182/blood.V128.22.950.950

Published: 2016

Journal Articles

A thrombopoietin receptor antagonist is capable of depleting myelofibrosis hematopoietic stem and progenitor cells

Xiaoli Wang, David Haylock, Cing Siang Hu, Wioleta Kowalczyk, Tianbo Jiang, Jiajing Qiu, Goar Mosoyan, Wu He, Netonia Marshall, John Mascarenhas, Anna Tarasova, Joshua Brody, David Winkler, Ronald Hoffman

Blood (2016) 127 (26): 3398–3409.

https://doi.org/10.1182/blood-2015-10-674465

Published: 2016

Includes: Supplemental data

Journal Articles

Characterization and Isolation of Splenic Littoral Cells, a Possible Cellular Niche for Extramedullary Hematopoiesis in Myelofibrosis

Jiajing Qiu, PhD, Xiaoli Wang, MD, Mohamed E Salama, MD, Ronald Hoffman, MD

Blood (2015) 126 (23): 3594.

https://doi.org/10.1182/blood.V126.23.3594.3594

Published: 2015

Journal Articles

Thrombopoietin Affects the Behavior of Myelofibrosis Stem Cells

Xiaoli Wang, Cing Siang Hu, Yan Li, Ronald Hoffman, MD

Blood (2014) 124 (21): 2145.

https://doi.org/10.1182/blood.V124.21.2145.2145

Published: 2014

Journal Articles

A Thrombopoietin Antagonist Is Capable of Affecting Stem and Progenitor Cells of Patients with Myelofibrosis

Xiaoli Wang, David Haylock, Cing Siang Hu, Goar Mosoyan, Dave Winkler, Ronald Hoffman, MD

Blood (2014) 124 (21): 819.

https://doi.org/10.1182/blood.V124.21.819.819

Published: 2014

Journal Articles

Specific and Recurrent Cytogenomic Abnormalities Originate in the Spleens of Myelofibrosis Patients and Contribute to Clonal Diversity and Disease Progression

Vesna Najfeld, PhD, Joseph Tripodi, MS, Xiaoli Wang, MD PhD, Myron Schwartz, MD, Marina Kremyanskaya, MDPhD, Edward Cytryn, Sharon Zirkiev, Raajit K. Rampal, MD, PhD, John O Mascarenhas, MD MS, Ronald Hoffman, MD

Blood (2014) 124 (21): 1871.

https://doi.org/10.1182/blood.V124.21.1871.1871

Published: 2014

NARROW

A Single Center Retrospective Study on the Efficacy of Haploidentical Hematopoietic Stem Cell Transplantation in Patients with Myeloid Neoplasms over 50 Years Old

TL-895, a Highly Selective, Covalent Inhibitor of Bruton's Tyrosine Kinase (BTK), Sensitizes Myeloproliferative Neoplasm (MPN)-Blast Phase Stem Cells to Navtemadlin By Targeting Intrinsic Dysregulated MDM2/p53 and NF-Κb Pathways and Disrupting the Protective Tumor Microenvironment (TME)

Oral Decitabine/Cedazuridine Is a Tolerable and Effective Ambulatory Regimen for Patients with Advanced Myeloproliferative Neoplasms

Transcriptional and Epigenetic Dysregulation Drives Erythroid and Megakaryocyte Differentiation Bias in the Spleens of Patients with Advanced Myelofibrosis

Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies

Antigen-guided depletion of anti-HLA antibody–producing cells by HLA-Fc fusion proteins

Pharmacodynamic Analysis of CAR-T Cell Persistence in Patients with Hematologic Malignancies Treated with NKTR-255, an IL-15 Receptor Agonist That Enhances CD8 + T-Cells: Preliminary Results from a Phase 1 Study

Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies

Navtemadlin (KRT-232), a Small Molecule MDM2 Inhibitor, Is More Effective Than Decitabine Against Myeloproliferative Neoplasm-Blast Phase in a Patient-Derived Xenograft Model

The Genetic Architecture of Myeloproliferative Neoplasms-Blast Phase (MPN-BP) Stem Cells

Combination Treatment with Imetelstat, a Telomerase Inhibitor, and Ruxolitinib Depletes Myelofibrosis Hematopoietic Stem Cells and Progenitor Cells

Myeloproliferative Neoplasm (MPN) Blastic Transformation Occurs at the Level of Hematopoietic Stem Cells

Myeloproliferative Neoplasm (MPN) Blastic Transformation Occurs at the Level of Both Short and Long Term Hematopoietic Stem Cells

Imetelstat, a Telomerase Inhibitor, Is Capable of Depleting Myelofibrosis Hematopoietic Stem Cells and Progenitor Cells

The Thrombopoietin Receptor (MPL) Is a Selective Marker for the Identification of Hematopoietic Stem Cells from Myelofibrosis Patients

A thrombopoietin receptor antagonist is capable of depleting myelofibrosis hematopoietic stem and progenitor cells

Characterization and Isolation of Splenic Littoral Cells, a Possible Cellular Niche for Extramedullary Hematopoiesis in Myelofibrosis

Thrombopoietin Affects the Behavior of Myelofibrosis Stem Cells

A Thrombopoietin Antagonist Is Capable of Affecting Stem and Progenitor Cells of Patients with Myelofibrosis

Specific and Recurrent Cytogenomic Abnormalities Originate in the Spleens of Myelofibrosis Patients and Contribute to Clonal Diversity and Disease Progression

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only